A Phase III Open-label, Randomized Study of Datopotamab Deruxtecan (Dato DXd) with or without Durvalumab Versus Investigator's Choice of Therapy in Patients with Stage I-III Triple-negative Breast Cancer who have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes Following Neoadjuvant Systemic Therapy and Surgical Resection (D926XC00001)
Details
This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.
Eligibility
You can join if...
Inclusion Criteria
-Patients at least 18 years of age at the time of screening
-Patients with histologically confirmed invasive triple negative breast cancer
Exclusion Criteria
Patients with stage IV (metastatic) triple negative breast cancer
-Patients with any concurrent anticancer treatment
-Patients with prior invasive breast cancer, or evidence of recurrent disease following preoperative therapy and surgery